TechnoDerma Medicines Inc., a Zhejiang-based developer of dermatology small molecules, has reportedly raised “tens of millions” of renminbi in a Series A+ financing round. The funding was led by Chengdu Biological City No. 1 Equity Investment Fund Partnership and Chengdu High-tech New Economy Venture Capital. The proceeds will be used to advance the company’s pipeline of innovative dermatology treatments.
Pipeline Progress and Clinical Development
TechnoDerma’s lead candidate, TDM-105795, is a small molecule drug for the treatment of androgen alopecia (AGA) and is designed for external use. The drug concluded its Phase I study in December 2022 and is expected to enter Phase II trials in March of this year. Another key asset, TDM-180935, is an atopic dermatitis (AD) treatment for external use that is currently undergoing a Phase I clinical study in the United States. These programs highlight TechnoDerma’s commitment to addressing significant unmet needs in dermatology.
Collaboration with University of Michigan
In addition to its clinical programs, TechnoDerma is collaborating with the University of Michigan on research related to skin scars. The partnership focuses on optimizing lead compounds to develop novel treatments for scar management, further expanding TechnoDerma’s research and development capabilities in dermatology.
Future Outlook
The Series A+ financing round positions TechnoDerma to accelerate the development of its pipeline, leveraging its expertise in small molecule drugs to address prevalent dermatological conditions. With ongoing clinical trials and strategic collaborations, TechnoDerma is poised to make a meaningful impact in the global dermatology market, improving patient outcomes through innovative therapies.-Fineline Info & Tech
